Launched in September 2017, the Helium Alpha fund relies on a quantitative equity long/short hybrid strategy, also called Quantamental which combines quantitative and fundamental portfolio management approaches.
Invested in Europe, Helium Alpha is an absolute performance fund moderately correlated with the equity markets.
| session | 3 years | 5 years | 10 years | Launch | |
|---|---|---|---|---|---|
| Accumulated Performance | 2.9% | 7.6% | 5.9% | - | 3% |
| Annualized Performance | 2.9% | 2.5% | 1.1% | - | 0.5% |
| % positive months | 38.5% | 51.4% | 47.5% | - | 51.3% |
| Perf. Monthly Average | 0.2% | 0.2% | 0.1% | - | - |
| Annualized Volatility | 4.9% | 4.9% | 5.9% | - | 5.9% |
| Sharpe Ratio | -0.2 | 0.2 | 0.1 | - | - |
| Drawdown Max | -3.3% | -5.7% | -8.5% | - | -13.5% |
This is a marketing communication. Past performance is no guarantee of future performance. The investment presents a risk of capital loss. Before any investment, please refer to the risks and various costs of each share class available in the prospectus and the KIDs.
Performances since inception in %
| January | February | March | April | May | June | July | August | September | October | November | December | Ytd Perf% | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -0.60% | 0.79% | 2.75% | 2.95% | |||||||||
| 2023 | -1.87% | -1.59% | 0.71% | -0.20% | -0.42% | 0.90% | -0.88% | -0.22% | -0.63% | 2.46% | -0.95% | 0.18% | -2.56% |
| 2022 | -1.58% | 0.31% | 2.34% | -0.89% | -1.26% | 2.19% | 1.19% | 0.83% | 0.01% | 0.82% | -0.46% | -0.07% | 3.38% |
| 2021 | 1.20% | 0.77% | 3.15% | 1.62% | 2.30% | -0.95% | 1.61% | -1.46% | 1.83% | 0.01% | -0.73% | 1.78% | 11.60% |
| 2020 | 1.26% | -1.04% | -1.22% | 0.87% | 0.23% | -0.71% | 0.56% | -1.35% | 0.04% | -1.54% | -1.87% | -1.35% | -6.00% |
| 2019 | 2.30% | 1.36% | 0.36% | -1.69% | 0.11% | -0.14% | 0.00% | -0.69% | -0.63% | -0.55% | 1.29% | -1.17% | 0.47% |
| 2018 | 0.74% | -1.59% | -0.40% | 1.11% | 0.13% | -1.91% | 0.22% | 0.14% | 0.02% | -2.22% | -3.15% | -0.56% | -7.37% |
| 2017 | 0.54% | 0.85% | -0.36% | 1.62% | 2.66% |
This is a marketing communication. Past performance is no guarantee of future performance. The investment presents a risk of capital loss. Before any investment, please refer to the risks and various costs of each share class available in the prospectus and the KIDs.
Information elements
| Inception | 22/09/2017 |
|---|---|
| Legal status | SICAV - UCITS |
| Volatility target | 5% - 7% |
| Recommended investment period | 5 years |
| Liquidity / NAV | Weekly |
| Deadline | Thursday before 5 pm CET |
| Senior Manager | Olivier Leymarie |
| Code ISIN | LU1685859180 |
| Code Bloomberg | HEALBEC LX |
| SFDR | Article 8 |
| Base currency | EUR |
|---|---|
| Domicile | Luxembourg |
| Administrator | CACEIS Bank Luxembourg |
| Auditor | Deloitte & Touche |
| Minimum initial subscription | EUR 5 000 |
| Management fees | 2.00% |
| Performance fees | 20% High Water Mark |
| Hurdle | ESTR |
| Assignment result | Capitalization |